An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States-Reference-Cited by-同舟云学术

An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States

Published:2022-12 Issue:12 Volume:22 Page:e1092-e1099
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Chihara Dai,Johnston Karissa^ORCID,Bolatova Talshyn,Szabo Shelagh^ORCID,Kalsekar Anupama,Mutebi Alex,Yang Huiying,Liu Yangyang,Attinson Dionna,Hutchings Martin^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference32 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016

2. Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts (www.seer.cancer.gov) 2020 Available at: https://seer.cancer.gov/statfacts.

3. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood,2006

4. Estimating disease prevalence and incidence using administrative data: some assembly required;Ward;J Rheumatol,2013

5. How important are estimates of cancer prevalence?;Giles;Ann Oncol,2002

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: A retrospective claims analysis (2015–2020);Journal of Medical Economics;2024-09-10

2. Aligning outcomes: DLBCL prognosis at a 4th Level University Hospital in Bogotá is comparable to high-income nations, identification of additional prognostic markers for overall survival and relapse;ecancermedicalscience;2024-06-20

3. Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation;BMC Cancer;2024-04-08

4. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis;Advances in Therapy;2024-02-02

5. Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab;Clinical Lymphoma Myeloma and Leukemia;2023-11